Abstract
Owing to therapeutic progress, the role of ABC-transporters in infectious and autoimmune inflammatory CNS-diseases has recently gained considerable attention. In HIV-encephalitis and HIV-associated neurocognitive disorders, ABC-transporters are discussed to contribute to limited CNS-penetration and -retention of antiviral agents. In multiple sclerosis and its animal model experimental autoimmune encephalomyelitis, ABC-transporters may be involved in pathogenesis and treatment response alike. A prospective pharmacogenetic study is currently underway to examine the predictive role of genetic variations in ABC-transporters for treatment response and adverse events to mitoxantrone, a therapeutic agent used in aggressive MS. These approaches may aid in individualized treatment with this cytostatic anthracenedione, addressing its narrow therapeutic index with potentially fatal side effects. Finally, understanding regulation and function of ABC-transporters under inflammatory conditions may also optimize ABC-transporter-related treatment strategies in other neurological diseases (e.g. neurodegenerative, and neurovascular) where neuroinflammatory mechanisms have gained considerable attention as important contributors to pathogenesis.
Keywords: multiple sclerosis, HIV-associated neurocognitive disorders, mitoxantrone, experimental autoimmune encephalomyelitis, cytokines, protease inhibitors, antiretroviral agents, biomarkers, mRNA-expression, drug metabolism
Current Pharmaceutical Design
Title: ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Volume: 17 Issue: 26
Author(s): A. Chan, R. Gold and N. von Ahsen
Affiliation:
Keywords: multiple sclerosis, HIV-associated neurocognitive disorders, mitoxantrone, experimental autoimmune encephalomyelitis, cytokines, protease inhibitors, antiretroviral agents, biomarkers, mRNA-expression, drug metabolism
Abstract: Owing to therapeutic progress, the role of ABC-transporters in infectious and autoimmune inflammatory CNS-diseases has recently gained considerable attention. In HIV-encephalitis and HIV-associated neurocognitive disorders, ABC-transporters are discussed to contribute to limited CNS-penetration and -retention of antiviral agents. In multiple sclerosis and its animal model experimental autoimmune encephalomyelitis, ABC-transporters may be involved in pathogenesis and treatment response alike. A prospective pharmacogenetic study is currently underway to examine the predictive role of genetic variations in ABC-transporters for treatment response and adverse events to mitoxantrone, a therapeutic agent used in aggressive MS. These approaches may aid in individualized treatment with this cytostatic anthracenedione, addressing its narrow therapeutic index with potentially fatal side effects. Finally, understanding regulation and function of ABC-transporters under inflammatory conditions may also optimize ABC-transporter-related treatment strategies in other neurological diseases (e.g. neurodegenerative, and neurovascular) where neuroinflammatory mechanisms have gained considerable attention as important contributors to pathogenesis.
Export Options
About this article
Cite this article as:
Chan A., Gold R. and von Ahsen N., ATP-Binding Cassette Transporters in Inflammatory Brain Disease, Current Pharmaceutical Design 2011; 17(26) . https://dx.doi.org/10.2174/138161211797440131
DOI https://dx.doi.org/10.2174/138161211797440131 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy Gymnema sylvestre R. Br., an Indian Medicinal Herb: Traditional Uses, Chemical Composition, and Biological Activity
Current Pharmaceutical Biotechnology Murine Skin-resident γδT Cells Impair the Immune Response to HSV in Skin
Infectious Disorders - Drug Targets Natural Chemical Entities as Bioactive Moiety from Weaver Ant, <i>Oecophylla smaragdina</i>: An In Vitro and In-silico Study
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Immune System Modulates the Function of Adult Neural Stem Cells
Current Immunology Reviews (Discontinued) Recombinant Rhabdoviruses as Potential Vaccines for HIV-1 and Other Diseases
Current HIV Research Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Novel Opportunities to Study and Block Interactions between Viruses and Cell Surface Heparan Sulfates by using Dispirotripiperazines
Letters in Drug Design & Discovery Protein Bioinformatics Applied to Virology
Current Protein & Peptide Science Recent Advances in Antiviral Nucleoside and Nucleotide Therapeutics
Current Topics in Medicinal Chemistry HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology